乐普医疗：目前注射用透明质酸钠复合溶液、热玛吉已完成发补材料的提交工作

Core Viewpoint - The company is actively pursuing a strategic transformation and development in the dermatology sector, leveraging its expertise in biodegradable biomaterials and the promising outlook of the consumer healthcare market [1] Group 1: Strategic Focus - The company's strategic core is to utilize its technological advantages in biodegradable materials, such as PLLA, to extend its successful experience from the cardiovascular interventional field into dermatology [1] - The company aims to gradually expand its product portfolio to include hyaluronic acid and botulinum toxin among other diverse offerings [1] Group 2: Product Development - The company has successfully launched its self-developed polylactic acid facial filler (童颜针), injectable sodium hyaluronate solution (水光针), and cross-linked sodium hyaluronate gel, marking the initial formation of its dermatology injection product matrix [1] - Several products under development are progressing as planned, with the injectable sodium hyaluronate composite solution and Thermage having completed the submission of their materials [1]